Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.77
-0.2200-7.36%
Post-market: 2.890.1200+4.33%18:17 EDT
Volume:1.58M
Turnover:4.44M
Market Cap:315.78M
PE:-2.08
High:3.01
Open:2.96
Low:2.75
Close:2.99
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:67.88M
Volume Ratio:1.38
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:0.98
PE(LYR):-1.98

Loading ...

Perspective Therapeutics Wins EU Orphan Drug Status for [212Pb]VMT-α-NET in GEP-NETs

Reuters
·
Jul 28

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212PB]Vmt-Α-Net in Gep-Nets

THOMSON REUTERS
·
Jul 28

Perspective Therapeutics Announces Acceptance of Vmt-α-net Data for Oral Presentation at the Esmo Congress 2026

THOMSON REUTERS
·
Jul 18

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

GlobeNewswire
·
Jul 18

Perspective Therapeutics management to meet virtually with BTIG

TIPRANKS
·
Jul 11

Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-founder Schultz Moves to Advisor Role

Reuters
·
Jul 08

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Tenaya Therapeutics (TNYA)

TIPRANKS
·
Jul 06

Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline

TIPRANKS
·
Jul 02

Perspective Therapeutics management to meet virtually with BTIG

TIPRANKS
·
Jun 27

Perspective Therapeutics doses first meningioma patient in Phase 1/2a trial of [212Pb]VMT-α-NET

Reuters
·
Jun 03

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed With [212PB]Vmt-Α-Net in the Meningioma Cohort of a Phase 1/2a Study

THOMSON REUTERS
·
Jun 03

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

GlobeNewswire
·
Jun 03

Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer

TIPRANKS
·
Jun 01

H.C. Wainwright Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Jun 01

Perspective Therapeutics shareholders elect six directors at annual meeting

Reuters
·
May 28

Perspective Therapeutics reports 29% response rate in [212Pb]VMT01 melanoma cohort 3.0 mCi trial

Reuters
·
May 22

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

GlobeNewswire
·
May 22

Perspective Therapeutics doses first patients in two Phase 1/2a studies

TIPRANKS
·
May 18

Perspective Therapeutics doses first patient in new VMT-α-NET Phase 1/2a cohort

Reuters
·
May 18

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

THOMSON REUTERS
·
May 18